Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AngioNorm
- Development stage
- Unknown
- Lead developer
- OTCPharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AngioNorm (АнгиоНорм) is a multi-component herbal pharmaceutical product developed and marketed by OTCPharm (Otisipharm) in Russia. It is formulated as 100 mg film-coated tablets containing a dry extract derived from a standardized mixture of four medicinal plants: hawthorn fruits (*Crataegus*), licorice roots (*Glycyrrhiza*), horse chestnut seeds (*Aesculus hippocastanum*), and rose hip fruits (*Rosa*). The drug is standardized to contain flavonoids, specifically calculated as avicularin. AngioNorm is positioned as a systemic angioprotector with a complex pharmacological profile that includes antiplatelet, antithrombotic, angioprotective, and anti-inflammatory properties. It is primarily indicated for the symptomatic treatment of varicose veins and chronic venous insufficiency, where it works to improve microcirculation, enhance venous tone, and reduce the risk of thrombosis. It is available as an over-the-counter (OTC) medication.
- Brand names
- AngioNormАнгиоНорм
- Other names
- AngioNorm-OTCPharm
Beyond the preview
Go deeper on AngioNorm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AngioNorm.